^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Plasma-SeqSensei™ NSCLC Kit

    Company:
    Sysmex Corp
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    The Plasma-SeqSensei™ (PSS) NSCLC RUO (research use only) Kit detects mutations in circulating tumour DNA (ctDNA) from plasma in patients with non-small cell lung cancer. The kit uses next generation sequencing for the detection and identification of mutations in BRAF, EGFR, KRAS, and PIK3CA genes in human cfDNA isolated from blood plasma which play a significant role in the development of NSCLC and are relevant biomarkers for prognosis, choice of therapy as well as monitoring of recurrence and therapy response.
    Cancer:
    Non Small Cell Lung Cancer
    Gene:
    BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), KRAS (KRAS proto-oncogene GTPase), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    Method:
    Next-Generation Sequencing (NGS) / Circulating tumor DNA (ctDNA)